Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria, 5 Allergy Therapeutics (UK) Ltd, Worthing, United Kingdom. RATIONALE: The results of this Phase II study [EudraCT 2017-000333-31 ] evaluated the dose response relationship for a modified grass allergen subcutaneous immunotherapy (SCIT) product (1.0 ml) with modified allergen tyrosine adsorbate (MATA) and monophosphoryl lipid A (MPL) adjuvants for the treatment of allergic rhinoconjunctivitis (ARC) due to grass pollen. METHODS: In total 447 patients with grass pollen-induced ARC were enrolled in this randomized, double-blind, placebo-controlled, parallel group study. Patients were randomized to one of five dose regimens of 5100, 14400, 27600 and 35600 SU and placebo. As a secondary endpoint the immunoglobulin markers (total IgE, grass-specific IgE, grass-specific IgG4 and specific IgE/total IgE ratio) were evaluated. RESULTS: For all immunoglobulin markers a strong statistically significant dose-response was shown for a wide range of cumulative doses from 5100 SU to 35600 SU. Grass-specific IgE, grass-specific IgG4 and specific IgE/total IgE ratio demonstrated statistically significant increases compared to placebo for all cumulative doses (P<0.01), including the currently marketed dose of 5100 SU in Europe. CONCLUSIONS: An ultra-short course of 6 injections with allergoid grass SCIT treatment with adjuvants MATA and MPL is associated with significant increases in immunoglobulin markers for a wide range of cumulative dose levels indicating a strong therapeutic response.
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Experience with Pharmacist Prepared Pre-filled SCIT Dosing in an Urban Allergy Clinic 2 Parkland Health and Hospital System, Dallas, TX. RATIONALE: In the U.S., subcutaneous immunotherapy (SCIT) doses are typically prepared by medical staff removing a given volume from an extract vial at a patient's injection visit. We report a novel methodology using pharmacist-prepared individual SCIT doses at an urban county hospital. METHODS: SCIT extracts are prepared by a pharmacist using dosing recommendations in the U.S. practice parameters. Individual SCIT doses are prepared by a pharmacist prior to a patient's appointment based on the patient's dosing schedule. Doses are placed in labeled syringes in patientspecific baggies. Nurses administer the pre-filled syringes to patients at their appointment. We analyzed data from January 2014 to July 2018 using this methodology. RESULTS: A total of 4203 doses were prepared; 3811 (90.6%) injections were given and 54 doses were held (1.2% of doses prepared). There were a total of 2323 patient appointments and 191 missed appointments (8% of total appointments). There were a total of 36 systemic reactions (0.9% of injections given) ranging from grade 1a -2z, with no grade 3-5 reactions. This rate of systemic reactions per injection is similar to what has been reported in the published literature of approximately 0.2% (Cox et al, 2010) , and also comparable to previously reported incidences of non-fatal SCIT systemic reactions in two large cohorts. CONCLUSIONS: We describe a unique approach to delivering SCIT doses yielding a low rate of systemic reactions per injection and minimizing dosing errors. This method may be appropriate for multidisciplinary clinics with frequently changing staff to enhance patient safety. Princeton University, Princeton, NJ. RATIONALE: Asthma and obesity are two of the most significant chronic childhood diseases in the US and both are increasing in prevalence worldwide. As body mass index (BMI) increases, so does asthma risk, pointing to a pathophysiological link. However, while these diseases are common and severe, it remains unclear how they converge to affect pediatric immune function and increase infection severity. METHODS: Prospective systems immunometabolic study of pediatric asthma and obesity: obese asthmatics (OA), non-obese asthmatics (A), obese non-asthmatics (O) and non-obese and non-asthmatics (HC). Asthmatics were atopic patients recruited from Allergy clinic, with deep clinical characterization including sensitization and spirometry. To assess the underlying mechanisms of immune dysfunction we used peripheral blood mass cytometry (CyTOF), serum metabolomics, serum cytokine analysis and high dimensional systems immunology analytics to combine the deep immunometabolic profiling with clinical immunological and metabolic data on these patients. RESULTS: Pediatric atopic OA patients demonstrated alterations in T cell differentiation including increased CD8 T cell exhaustion. They also demonstrated altered serum metabolites including increased glutamate, which may underlie some of the immune dysfunction. Finally, altered vaccine responses were also connected to underlying immunometabolic dysregulation in obesity. CONCLUSIONS: These insights into the mechanistic links between metabolic disturbances and immune dysfunction in OA may improve understanding of the severe asthma exacerbations with viral upper respiratory infections seen in OA. We are currently focused on testing these mechanisms in mouse models of disease. Ideally, this will lead to identification of novel therapeutic targets for this challenging to manage patient population.
929

